

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians

70, 86-104

DOI: [10.3322/caac.21596](https://doi.org/10.3322/caac.21596)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Overall Survival in Heart Disease-Related Death in Non-Small Cell Lung Cancer Patients: Nonimmunotherapy Versus Immunotherapy Era: Population-Based Study. <i>Frontiers in Oncology</i> , 2020, 10, 572380.	1.3	3
2	Chemical and physical chitosan hydrogels as prospective carriers for drug delivery: a review. <i>Journal of Materials Chemistry B</i> , 2020, 8, 10050-10064.	2.9	85
3	Targeting STAT3 in Cancer Immunotherapy. <i>Molecular Cancer</i> , 2020, 19, 145.	7.9	423
4	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
5	The Critical Role of the Oncology Nurse as a Partner in the Management of Patients With Advanced Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 460-463.	1.0	5
6	Immunotherapy in older patients with cancer. <i>Biomedical Journal</i> , 2021, 44, 260-271.	1.4	19
7	Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. <i>Nature Communications</i> , 2020, 11, 4946.	5.8	120
8	Natural products and their derivatives: Promising modulators of tumor immunotherapy. <i>Journal of Leukocyte Biology</i> , 2020, 108, 493-508.	1.5	114
9	Metastatic Renal Cell Carcinoma Presenting as a Rapidly Enlarging Endotracheal Mass Due to Hyperprogression on Anti-PD1 Immunotherapy. <i>Ear, Nose and Throat Journal</i> , 2021, 100, 905S-907S.	0.4	3
10	Loco-regional drug delivery in oncology: current clinical applications and future translational opportunities. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 607-623.	2.4	10
11	Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 2054-2074.	5.7	65
12	Exosome-based immunotherapy: a promising approach for cancer treatment. <i>Molecular Cancer</i> , 2020, 19, 160.	7.9	241
13	Water extract of sporoderm-broken spores of <i>Ganoderma lucidum</i> enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110541.	2.5	12
14	B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5192.	1.8	24
15	Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data. <i>Cancer Medicine</i> , 2020, 9, 6576-6585.	1.3	21
16	Mechanogenetics for cellular engineering and cancer immunotherapy. <i>Current Opinion in Biotechnology</i> , 2020, 66, 88-94.	3.3	9
18	Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. <i>Cancer Treatment Reviews</i> , 2020, 90, 102089.	3.4	27
19	Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology. <i>Cells</i> , 2020, 9, 2102.	1.8	56

#	ARTICLE	IF	CITATIONS
20	Patients With Lung Cancer Have High Susceptibility of COVID-19: A Retrospective Study in Wuhan, China. <i>Cancer Control</i> , 2020, 27, 107327482096046.	0.7	17
21	DEAD-box RNA helicase protein DDX21 as a prognosis marker for early stage colorectal cancer with microsatellite instability. <i>Scientific Reports</i> , 2020, 10, 22085.	1.6	12
22	The role and economics of immunotherapy in solid tumour management. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 2020-2024.	0.5	4
23	Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2020, 11, 595655.	2.2	8
24	Recent updates on Sintilimab in solid tumor immunotherapy. <i>Biomarker Research</i> , 2020, 8, 69.	2.8	26
25	The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. <i>Frontiers in Endocrinology</i> , 2020, 11, 608422.	1.5	37
26	Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. , 2020, 8, e001198.		24
27	Perspective: Cell therapy, SARS-CoV-2, COVID-19, and James Lind. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e88.	0.6	2
28	Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination. <i>Cancers</i> , 2020, 12, 1295.	1.7	28
29	Abscopal effect in radioimmunotherapy. <i>International Immunopharmacology</i> , 2020, 85, 106663.	1.7	77
30	Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2020, 11, 1128.	2.2	29
31	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 47-68.	3.1	93
32	Nanotechnologies for enhancing cancer immunotherapy. <i>Nano Research</i> , 2020, 13, 2595-2616.	5.8	22
33	The Contribution of Epigenetics to Cancer Immunotherapy. <i>Trends in Immunology</i> , 2020, 41, 676-691.	2.9	133
34	GP130 Cytokines in Breast Cancer and Bone. <i>Cancers</i> , 2020, 12, 326.	1.7	29
35	Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. <i>Cancer Discovery</i> , 2020, 10, 783-791.	7.7	1,286
36	Cancer immunotherapy: Current applications and challenges. <i>Cancer Letters</i> , 2020, 480, 1-3.	3.2	19
37	Opportunistic bowel infection after corticosteroid dosage tapering in a stage IV lung cancer patient with tislelizumab-related colitis. <i>Thoracic Cancer</i> , 2020, 11, 1699-1702.	0.8	8

#	ARTICLE	IF	CITATIONS
38	Expression of PD-1 and Tim-3 is increased in skin of patients with bullous pemphigoid and pemphigus vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 486-492.	1.3	10
39	Improving safety of cancer immunotherapy via delivery technology. <i>Biomaterials</i> , 2021, 265, 120407.	5.7	22
40	PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. <i>Journal of Advanced Research</i> , 2021, 29, 45-54.	4.4	31
41	Evaluation of piggyBac-mediated anti-CD19 CAR cells after ex vivo expansion with aAPCs or magnetic beads. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 686-700.	1.6	4
42	Virulence-attenuated <i>Salmonella</i> engineered to secrete immunomodulators reduce tumour growth and increase survival in an autochthonous mouse model of breast cancer. <i>Journal of Drug Targeting</i> , 2021, 29, 430-438.	2.1	5
43	Molybdenum-based hetero-nanocomposites for cancer therapy, diagnosis and biosensing application: Current advancement and future breakthroughs. <i>Journal of Controlled Release</i> , 2021, 330, 257-283.	4.8	45
44	Considerations when treating high-grade pediatric glioma patients with immunotherapy. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 205-219.	1.4	5
45	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 77.e17-77.e25.	0.8	16
46	Construction and Validation of an Immune and Tumor Mutation Burden Based Prognostic Model in Lung Adenocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
47	Elucidating tumor immunosurveillance and immunoediting: a comprehensive review. <i>Ciencia Animal Brasileira</i> , 0, 22, .	0.3	1
48	Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy. <i>Cancer Discovery</i> , 2021, 11, 266-281.	7.7	99
49	Shocking HIV-1 with immunomodulatory latency reversing agents. <i>Seminars in Immunology</i> , 2021, 51, 101478.	2.7	11
50	Guillain-Barré syndrome in patients treated with immune checkpoint inhibitors. <i>Journal of Neurology</i> , 2021, 268, 2169-2174.	1.8	19
51	The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2313-2321.	2.0	35
52	Relationship between PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Canine Mammary Tumor. <i>Acta Scientiae Veterinariae</i> , 0, 49, .	0.2	0
53	Spatially-resolved proteomics and transcriptomics: An emerging digital spatial profiling approach for tumor microenvironment. <i>Visualized Cancer Medicine</i> , 2021, 2, 1.	0.5	9
54	Comorbidity and frailty assessment in renal cell carcinoma patients. <i>World Journal of Urology</i> , 2021, 39, 2831-2841.	1.2	7
55	Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment. <i>Neoplasia</i> , 2021, 23, 189-196.	2.3	38

#	ARTICLE	IF	CITATIONS
56	A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy. <i>Nature Communications</i> , 2021, 12, 1087.	5.8	62
57	Stimulation and Suppression of the Innate Immune System through Nanotechnology. <i>ACS Applied Nano Materials</i> , 2021, 4, 2303-2316.	2.4	5
58	CAR T cells targeting options in the fight against multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 37-45.	0.2	2
60	Polymeric Micelles in Cancer Immunotherapy. <i>Molecules</i> , 2021, 26, 1220.	1.7	22
61	Delivery of gefitinib with an immunostimulatory nanocarrier improves therapeutic efficacy in lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 926-935.	1.3	5
62	Using viral vectors to deliver local immunotherapy to glioblastoma. <i>Neurosurgical Focus</i> , 2021, 50, E4.	1.0	12
63	Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2021, 2021, 1-15.	0.9	77
64	Tackling cancer cell dormancy: Insights from immune models, and transplantation. <i>Seminars in Cancer Biology</i> , 2022, 78, 5-16.	4.3	9
65	Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles. <i>Journal of Nanobiotechnology</i> , 2021, 19, 58.	4.2	67
66	The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis. <i>Cancer Management and Research</i> , 2021, Volume 13, 1383-1393.	0.9	5
67	RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies. <i>Frontiers in Genetics</i> , 2020, 11, 598118.	1.1	18
68	Current advancements and future perspectives of immunotherapy in colorectal cancer research. <i>European Journal of Pharmacology</i> , 2021, 893, 173819.	1.7	91
69	Patient Perceptions of Treatment Benefit and Toxicity in Advanced Cancer: A Prospective Cross-Sectional Study. <i>JCO Oncology Practice</i> , 2021, 17, e119-e129.	1.4	8
70	ImmunoPET imaging of human CD8+ T cells with novel ⁶⁸ Ga-labeled nanobody companion diagnostic agents. <i>Journal of Nanobiotechnology</i> , 2021, 19, 42.	4.2	30
71	Synergy of Immunostimulatory Genetherapy with Immune Checkpoint Blockade Motivates Immune Response to Eliminate Cancer. <i>Advanced Functional Materials</i> , 2021, 31, 2100715.	7.8	23
72	The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy. <i>Journal of Controlled Release</i> , 2021, 331, 321-334.	4.8	35
73	Exploration of a Robust and Prognostic Immune Related Gene Signature for Cervical Squamous Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 625470.	1.6	11
74	Research advances in chimeric antigen receptor-modified T-cell therapy (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 484.	0.8	1

#	ARTICLE	IF	CITATIONS
75	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1396-1404.	3.0	56
76	Enhancing Cancer Immunotherapy Treatment Goals by Using Nanoparticle Delivery System. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 2389-2404.	3.3	17
77	Recent Progress of Alkyl Radicals Generation-Based Agents for Biomedical Applications. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100055.	3.9	21
78	Perspectives on Epigenetics and Cancer Immunotherapy: A Preface to Special Issue. <i>Cancers</i> , 2021, 13, 1452.	1.7	4
79	Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. <i>Supportive Care in Cancer</i> , 2021, 29, 5417-5423.	1.0	15
80	Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 642110.	1.3	32
81	Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis. <i>Frontiers in Oncology</i> , 2021, 11, 633032.	1.3	53
82	Epigenomics and immunotherapeutic advances in pediatric brain tumors. <i>Npj Precision Oncology</i> , 2021, 5, 34.	2.3	9
83	Therapeutic Targeting of the Tumor Microenvironment. <i>Cancer Discovery</i> , 2021, 11, 933-959.	7.7	646
84	Expected and non-expected immune-related adverse events detectable by CT. <i>European Journal of Radiology</i> , 2021, 138, 109617.	1.2	3
85	Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. <i>Vaccines</i> , 2021, 9, 509.	2.1	14
86	Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non-Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysis. <i>Clinical Lung Cancer</i> , 2021, 22, e889-e900.	1.1	9
87	Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis. <i>BMC Cancer</i> , 2021, 21, 634.	1.1	15
88	Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 35-44.	0.6	4
89	Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662392.	1.3	3
90	Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis. <i>Aging</i> , 2021, 13, 12691-12709.	1.4	1
91	A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662302.	1.3	10
92	Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies. <i>Cancers</i> , 2021, 13, 2607.	1.7	26

#	ARTICLE	IF	CITATIONS
93	CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3603-3616.	2.0	11
94	MelmmS: Predict Clinical Benefit of Anti-PD-1/PD-L1 Treatments Based on DNA Methylation in Non-small Cell Lung Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 676449.	1.1	10
95	Real-World Evidence of the Incidence of and Risk Factors for Type 1 Diabetes Mellitus and Hypothyroidism as Immune-Related Adverse Events Associated With Programmed Cell Death-1 Inhibitors. <i>Endocrine Practice</i> , 2021, 27, 586-593.	1.1	10
96	Immunological considerations and challenges for regenerative cellular therapies. <i>Communications Biology</i> , 2021, 4, 798.	2.0	44
97	Boosting immune system against cancer by resveratrol. <i>Phytotherapy Research</i> , 2021, 35, 5514-5526.	2.8	27
98	Multifaceted Role of the Transforming Growth Factor \hat{I}^2 on Effector T Cells and the Implication for CAR-T Cell Therapy. <i>Immuno</i> , 2021, 1, 160-173.	0.6	4
99	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021, 19, 270.	1.8	14
100	Chimeric antigen receptor <scp>T</scp>â€œcells safety: A pharmacovigilance and metaâ€œanalysis study. <i>American Journal of Hematology</i> , 2021, 96, 1101-1111.	2.0	14
101	Evolving treatments and future therapeutic targets in desmoplastic melanoma. <i>Melanoma Management</i> , 2021, 8, MMT56.	0.1	0
102	Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor. <i>Frontiers in Oncology</i> , 2021, 11, 589022.	1.3	20
103	Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 666909.	2.2	2
104	Immune checkpoint inhibitors: current status. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-002954.	0.8	1
105	Immune checkpoint inhibitorsâ€œrelated encephalitis in melanoma and non-melanoma cancer patients: a single center experience. <i>Supportive Care in Cancer</i> , 2021, 29, 7563-7568.	1.0	8
106	Sodium bicarbonate, an inorganic salt and a potential active agent for cancer therapy. <i>Chinese Chemical Letters</i> , 2021, 32, 3687-3695.	4.8	16
107	Spatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment. <i>Biotechnology Journal</i> , 2021, 16, e2100041.	1.8	65
108	CAR-macrophage: A new immunotherapy candidate against solid tumors. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111605.	2.5	92
109	Promising anticancer activity of polysaccharides and other macromolecules derived from oyster mushroom (<i>Pleurotus</i> sp.): An updated review. <i>International Journal of Biological Macromolecules</i> , 2021, 182, 1628-1637.	3.6	26
110	Oncolytic Adenovirus: Prospects for Cancer Immunotherapy. <i>Frontiers in Microbiology</i> , 2021, 12, 707290.	1.5	29

#	ARTICLE	IF	CITATIONS
111	Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1225-1232.	1.4	11
112	Immunotherapy-Related Cystitis: Case Report and Review of the Literature. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4321-4328.	1.0	12
113	Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review. <i>Frontiers in Immunology</i> , 2021, 12, 682262.	2.2	13
114	Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study. <i>BMC Cancer</i> , 2021, 21, 823.	1.1	9
115	Classification of Lung Adenocarcinoma Based on Immune Checkpoint and Screening of Related Genes. <i>Journal of Oncology</i> , 2021, 2021, 1-12.	0.6	6
116	Integrative medicine in the era of cancer immunotherapy: Challenges and opportunities. <i>Journal of Integrative Medicine</i> , 2021, 19, 291-294.	1.4	14
117	Dual mitigation of immunosuppression combined with photothermal inhibition for highly effective primary tumor and metastases therapy. <i>Biomaterials</i> , 2021, 274, 120856.	5.7	32
118	Gut and Endometrial Microbiome Dysbiosis: A New Emergent Risk Factor for Endometrial Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 659.	1.1	17
119	The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 667650.	1.3	8
120	A regulatory loop among CD276, miR-29c-3p, and Myc exists in cancer cells against natural killer cell cytotoxicity. <i>Life Sciences</i> , 2021, 277, 119438.	2.0	9
121	Perfluorooctyl bromide nanoemulsions holding MnO ₂ nanoparticles with dual-modality imaging and glutathione depletion enhanced HIFU-eliciting tumor immunogenic cell death. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 967-981.	5.7	16
123	Management and Clinical Outcome of Posterior Reversible Encephalopathy Syndrome in Pediatric Oncologic/Hematologic Diseases: A PRES Subgroup Analysis With a Large Sample Size. <i>Frontiers in Pediatrics</i> , 2021, 9, 678890.	0.9	6
124	Tying Small Changes to Large Outcomes: The Cautious Promise in Incorporating the Microbiome into Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7900.	1.8	3
125	Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 949-982.	2.7	72
126	Skin Deep: A Fascinating Case Report of Immunotherapy-Triggered, Treatment-Refractory Autoimmune Lichen Planus and Keratoacanthoma. <i>Case Reports in Oncology</i> , 2021, 14, 1189-1193.	0.3	6
127	Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	1.4	17
128	Fucoidan-Supplemented Diet Potentiates Immune Checkpoint Blockage by Enhancing Antitumor Immunity. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 733246.	1.8	12
129	Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal. <i>Journal of Nanobiotechnology</i> , 2021, 19, 243.	4.2	14

#	ARTICLE	IF	CITATIONS
130	Cellular based immunotherapy for primary liver cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 250.	3.5	12
131	Possible Immunotherapeutic Strategies Based on Carcinogen-Dependent Subgroup Classification for Oral Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 717038.	1.6	2
132	Pyroptosis, a new bridge to tumor immunity. <i>Cancer Science</i> , 2021, 112, 3979-3994.	1.7	113
133	Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. <i>ELife</i> , 2021, 10, .	2.8	33
134	Biosynthesis, characterization, and application of Cu ₂ O nanoparticles originated from Cressa leaf extract as an efficient green catalyst in the synthesis of some chromenes. <i>Journal of the Iranian Chemical Society</i> , 2022, 19, 1261-1270.	1.2	14
135	Lymph Nodes-On-Chip: Promising Immune Platforms for Pharmacological and Toxicological Applications. <i>Frontiers in Pharmacology</i> , 2021, 12, 711307.	1.6	21
136	Susceptibility of lung cancer patients to COVID-19: A review of the pandemic data from multiple nationalities. <i>Thoracic Cancer</i> , 2021, 12, 2637-2647.	0.8	10
137	Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases. <i>BioMed Research International</i> , 2021, 2021, 1-17.	0.9	10
138	Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9118.	1.8	55
139	Pyroptosis, metabolism, and tumor immune microenvironment. <i>Clinical and Translational Medicine</i> , 2021, 11, e492.	1.7	119
140	Advances in culture methods for acute myeloid leukemia research. <i>Oncoscience</i> , 2021, 8, 82-90.	0.9	2
141	Immune checkpoint inhibitor combined with anti-angiogenesis agent inhibits metastasis of advanced adenoid cystic carcinoma of the tongue base to the lung: a case report. <i>Annals of Translational Medicine</i> , 2021, 9, 1353-1353.	0.7	1
142	CAR T cells: Building on the CD19 paradigm. <i>European Journal of Immunology</i> , 2021, 51, 2151-2163.	1.6	43
143	Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1752.	3.3	13
144	Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 704336.	1.3	29
145	HCG18 Participates in Vascular Invasion of Hepatocellular Carcinoma by Regulating Macrophages and Tumor Stem Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 707073.	1.8	8
146	Enteric plexus neuropathy associated with PD-L1 blockade in a patient with small-cell lung cancer. <i>Immunotherapy</i> , 2021, 13, 1085-1092.	1.0	3
147	Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database. <i>International Immunopharmacology</i> , 2021, 98, 107818.	1.7	12

#	ARTICLE	IF	CITATIONS
148	Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid. <i>Frontiers in Immunology</i> , 2021, 12, 731774.	2.2	5
149	Advances in the Genetically Engineered KillerRed for Photodynamic Therapy Applications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10130.	1.8	12
150	Immunotherapy of Multiple Myeloma: Promise and Challenges. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 343-371.	2.7	11
151	A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 707211.	2.2	9
152	Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. <i>Expert Opinion on Drug Safety</i> , 2021, , 1-13.	1.0	0
153	Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents. <i>Kidney Research and Clinical Practice</i> , 2021, 40, 344-354.	0.9	5
154	Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling. <i>Pharmacological Research</i> , 2021, 171, 105574.	3.1	38
155	Spinal metastases 2021: a review of the current state of the art and future directions. <i>Spine Journal</i> , 2021, 21, 1414-1429.	0.6	38
156	Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review. <i>Immunotherapy</i> , 2021, 13, 1071-1078.	1.0	7
157	Embracing cancer immunotherapy with vital micronutrients. <i>World Journal of Clinical Oncology</i> , 2021, 12, 712-724.	0.9	10
158	Systematic review of the immunological landscape of Wilms tumors. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 454-467.	2.0	25
159	TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 732125.	2.2	10
160	Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 736030.	2.2	20
161	Nivolumab-associated DRESS in a genetic susceptible individual. , 2021, 9, e002879.		16
162	Ocular side effects of checkpoint inhibitors. <i>Survey of Ophthalmology</i> , 2021, 66, 951-959.	1.7	16
163	Proteomic biomarker technology for cancer immunotherapy. , 2022, , 357-397.		0
164	Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 596-603.	0.7	6
165	Overcoming Resistance to Drugs Targeting KRAS Mutation. <i>Innovation(China)</i> , 2020, 1, 100035.	5.2	44

#	ARTICLE	IF	CITATIONS
166	Translational approaches to treating dynamical diseases through <i>in silico</i> clinical trials. <i>Chaos</i> , 2020, 30, 123128.	1.0	21
167	Perspective: SARS-CoV-2, COVID-19 and Haematologists. <i>Acta Haematologica</i> , 2021, 144, 117-121.	0.7	12
168	Construction of a new tumor immunity-related signature to assess and classify the prognostic risk of ovarian cancer. <i>Aging</i> , 2020, 12, 21316-21328.	1.4	6
169	Clinical challenges in cancer patients with COVID-19: Aging, immunosuppression, and comorbidities. <i>Aging</i> , 2020, 12, 24462-24474.	1.4	17
170	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. <i>Antibodies</i> , 2020, 9, 17.	1.2	14
171	Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	6
172	Critical care management of chimeric antigen receptor T-cell therapy recipients. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 78-93.	157.7	29
173	Silk Embolic Material for Catheter-Directed Endovascular Drug Delivery. <i>Advanced Materials</i> , 2022, 34, e2106865.	11.1	19
174	Identification of Three Core Secretome Genes Associated with Immune Infiltration in High Tumor Mutation Burden Across 14 Major Solid Tumors. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6755-6767.	0.8	2
175	CAR T-cell therapy and critical care. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1318-1325.	1.0	18
176	Multi-omics analysis of m6A modification-related patterns based on m6A regulators and tumor microenvironment infiltration in lung adenocarcinoma. <i>Scientific Reports</i> , 2021, 11, 20921.	1.6	2
177	Novel Cancer Therapeutics and Implications for Rehabilitation. <i>Current Physical Medicine and Rehabilitation Reports</i> , 2021, 9, 224-229.	0.3	0
178	Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency. <i>Frontiers in Endocrinology</i> , 2021, 12, 722586.	1.5	4
179	Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma. <i>Immunotherapy</i> , 2021, 13, 1387-1393.	1.0	2
180	Immunotherapy in Cancer Management: A Literature Review of Clinical Efficacy of Pembrolizumab in the Non-small Cell Lung Cancer Treatment. <i>Advanced Pharmaceutical Bulletin</i> , 2021, , .	0.6	3
181	Pembrolizumab: The Nut Cracker. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 393-396.	0.1	0
182	Side effects and management in immunotherapy based on immune checkpoint inhibitors. <i>World Chinese Journal of Digestology</i> , 2020, 28, 755-764.	0.0	1
183	Immune-based Therapies—What the Emergency Physician Needs to Know. <i>Emergency Medicine Clinics of North America</i> , 2021, 40, 135-148.	0.5	0

#	ARTICLE	IF	CITATIONS
184	Biosynthesized CuO as a Green and Efficient Nanophotocatalyst in the Solvent-Free Synthesis of Some Chromeno[4, 3-b]Chromenes. Studying anti- Gastric Cancer Activity. Polycyclic Aromatic Compounds, 2022, 42, 7071-7090.	1.4	10
185	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 4073-4126.	0.8	580
186	Pharmacokinetics, Pharmacodynamics, and Toxicology Aspects of Immunotherapeutics. , 2021, , 195-214.		0
187	Fighting microbial pathogens by integrating host ecosystem interactions and evolution. BioEssays, 2021, 43, 2000272.	1.2	5
188	Impact of antitumor regimens on the outcomes of cancer patients with COVID-19: a pooled analysis. Journal of Zhejiang University: Science B, 2021, 22, 876-884.	1.3	1
189	Gut Microbiota: A Potential Target for Cancer Interventions. Cancer Management and Research, 2021, Volume 13, 8281-8296.	0.9	10
190	Winning the Fight Against Cancer. Annals of the Academy of Medicine, Singapore, 2020, 49, 779-788.	0.2	1
191	Emerging Monoclonal Antibodies for the Treatment of Multiple Myeloma. , 0, , .		1
192	Natural killer cells: of-the-shelf cytotherapy for cancer immunosurveillance. American Journal of Cancer Research, 2021, 11, 1770-1791.	1.4	3
194	Ionic liquids in pharmaceutical industry: A systematic review on applications and future perspectives. Journal of Molecular Liquids, 2022, 349, 118145.	2.3	67
195	Integrated analysis of immune infiltration in esophageal carcinoma as prognostic biomarkers. Annals of Translational Medicine, 2021, 9, 1697-1697.	0.7	4
196	Dual Tumor Microenvironment Remodeling by Glucose-Containing Radical Copolymer for MRI-Guided Photoimmunotherapy. Advanced Materials, 2022, 34, e2107674.	11.1	52
197	Comprehensive Analysis of the Immune and Prognostic Implication of MMP14 in Lung Cancer. Disease Markers, 2021, 2021, 1-21.	0.6	4
198	Nanotherapeutics for immune network modulation in tumor microenvironments. Seminars in Cancer Biology, 2022, 86, 1066-1087.	4.3	3
199	TGF- β 2 Signaling and Resistance to Cancer Therapy. Frontiers in Cell and Developmental Biology, 2021, 9, 786728.	1.8	66
200	Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment. Journal of Controlled Release, 2022, 341, 399-413.	4.8	16
201	CCL11 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Breast Cancer. SSRN Electronic Journal, 0, , .	0.4	0
202	Pulmonary Toxicities of Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1342, 357-375.	0.8	4

#	ARTICLE	IF	CITATIONS
203	Immunotherapy toxicity: identification and management. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 1-17.	1.1	24
204	A Bioinformatic Analysis of Immune-Related Prognostic Genes in Clear Cell Renal Cell Carcinoma Based on TCGA and GEO Databases. <i>International Journal of General Medicine</i> , 2022, Volume 15, 325-342.	0.8	3
205	Recent advances in polysaccharides from edible and medicinal <i>Polygonati rhizoma</i> : From bench to market. <i>International Journal of Biological Macromolecules</i> , 2022, 195, 102-116.	3.6	34
206	Combinational application of metal-organic frameworks-based nanozyme and nucleic acid delivery in cancer therapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1773.	3.3	16
207	Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy. <i>Translational Oncology</i> , 2022, 16, 101309.	1.7	5
208	Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage. <i>BMC Medicine</i> , 2021, 19, 322.	2.3	0
209	Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 802672.	2.2	2
210	Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	1
211	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1455-1466.	1.5	7
212	Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. <i>Theranostics</i> , 2022, 12, 747-766.	4.6	28
213	Proposal for a general framework for the administration of anticancer immunotherapy in a hospital-at-home care. <i>Bulletin Du Cancer</i> , 2022, 109, 98-105.	0.6	1
214	Harnessing big data to characterize immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 269-280.	12.5	41
215	Semaphorins as Potential Immune Therapeutic Targets for Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 793805.	1.3	3
216	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. , 2022, 10, e003779.		34
217	Navigating Regulations in Gene and Cell Immunotherapy. <i>Cancer Drug Discovery and Development</i> , 2022, , 141-164.	0.2	0
218	Clinical Significance of BTLA, CD27, CD70, CD28 and CD80 as Diagnostic and Prognostic Markers in Ovarian Cancer. <i>Diagnostics</i> , 2022, 12, 251.	1.3	6
219	Biomarkers related to immune checkpoint inhibitors therapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112470.	2.5	14
220	OUP accepted manuscript. <i>Briefings in Bioinformatics</i> , 2022, , .	3.2	11

#	ARTICLE	IF	CITATIONS
221	Immune Microenvironment Characteristics of Urachal Carcinoma and Its Implications for Prognosis and Immunotherapy. <i>Cancers</i> , 2022, 14, 615.	1.7	7
222	Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors. <i>Translational Cancer Research</i> , 2022, 11, 252-261.	0.4	6
223	Retrospective study evaluating immune-related adverse events in cancer patients treated with pembrolizumab. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522210743.	0.5	2
224	In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 809754.	1.3	24
225	Cancer Immunotherapies: What the Perioperative Physician Needs to Know. <i>Current Oncology Reports</i> , 2022, 24, 399-414.	1.8	6
226	Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review. <i>British Journal of Ophthalmology</i> , 2023, 107, 901-905.	2.1	3
227	Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 809304.	1.3	23
228	Selenopeptide Nanomedicine Activates Natural Killer Cells for Enhanced Tumor Chemoimmunotherapy. <i>Advanced Materials</i> , 2022, 34, e2108167.	11.1	32
229	Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy. <i>Cancer Cell</i> , 2022, 40, 255-276.	7.7	45
230	Aptamer-functionalized targeted siRNA delivery system for tumor immunotherapy. <i>Biomedical Materials (Bristol)</i> , 2022, 17, 024108.	1.7	8
231	A Novel Immune Classification for Predicting Immunotherapy Responsiveness in Patients With Adamantinomatous Craniopharyngioma. <i>Frontiers in Neurology</i> , 2021, 12, 704130.	1.1	4
232	Survivorship for Individuals Living With Advanced and Metastatic Cancers: National Cancer Institute Meeting Report. <i>Journal of the National Cancer Institute</i> , 2022, 114, 489-495.	3.0	33
233	Celiac Disease After Administration of Immune Checkpoint Inhibitors: A Case Report. <i>Frontiers in Immunology</i> , 2021, 12, 799666.	2.2	5
234	Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events. <i>Frontiers in Oncology</i> , 2021, 11, 757069.	1.3	9
235	The efficacy and safety of chimeric antigen receptor T cells in digestive system cancers: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2021, .	0.7	1
236	ä,è·æŠ—è,ç~çš,,âÇžæ·â†æ¬æ·â°”ç”ç©¶è¿à±•. <i>Scientia Sinica Vitae</i> , 2022, , .	0.1	1
238	Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo. <i>Molecules</i> , 2022, 27, 1482.	1.7	8
239	Multi-faced roles of reactive oxygen species in anti-tumor T cell immune responses and combination immunotherapy. <i>Exploration of Medicine</i> , 0, , 77-98.	1.5	3

#	ARTICLE	IF	CITATIONS
240	Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents. <i>Cancers</i> , 2022, 14, 953.	1.7	16
241	Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 847350.	1.3	6
242	Enhanced antitumor chemo-immunotherapy by local co-delivery of chemotherapeutics, immune checkpoint blocking antibody and IDO inhibitor using an injectable polypeptide hydrogel. <i>Journal of Polymer Science</i> , 2022, 60, 1595-1609.	2.0	9
243	RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas. <i>Scientific Reports</i> , 2022, 12, 3122.	1.6	9
244	Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 295-306.	1.3	16
245	Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 68.	3.5	115
246	Immunotherapy Associated Neurotoxicity in Pediatric Oncology. <i>Frontiers in Oncology</i> , 2022, 12, 836452.	1.3	5
247	A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy. <i>Experimental Hematology and Oncology</i> , 2022, 11, 15.	2.0	19
248	Advances in the Novel Nanotechnology for Targeted Tumor Therapy by Transdermal Drug Delivery. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 2708-2714.	0.9	2
249	Breaking Immunosuppressive Barriers by Engineered Nanoplatfoms for Turning Cold Tumor to Hot. <i>Advanced Therapeutics</i> , 2022, 5, .	1.6	3
250	Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: supportive care implications and recommendations. <i>Supportive Care in Cancer</i> , 2022, 30, 6369-6373.	1.0	7
251	Large-cohort humanized NPI mice reconstituted with CD34 hematopoietic stem cells are feasible for evaluating preclinical cancer immunotherapy. <i>FASEB Journal</i> , 2022, 36, e22244.	0.2	4
252	GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 857308.	2.2	28
253	Direct and indirect engagement of dendritic cell function by antibodies developed for cancer therapy. <i>Clinical and Experimental Immunology</i> , 2022, 209, 64-71.	1.1	5
254	Solid Tumors and Kinase Inhibition: Management and Therapy Efficacy Evolution. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3830.	1.8	2
255	Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives. <i>Frontiers in Oncology</i> , 2022, 12, 836891.	1.3	5
256	Cross-Talk Between m6A- and m5C-Related lncRNAs to Construct a Novel Signature and Predict the Immune Landscape of Colorectal Cancer Patients. <i>Frontiers in Immunology</i> , 2022, 13, 740960.	2.2	11
257	Development of a Localized Drug Delivery System with a Step-by-Step Cell Internalization Capacity for Cancer Immunotherapy. <i>ACS Nano</i> , 2022, 16, 5778-5794.	7.3	18

#	ARTICLE	IF	CITATIONS
258	Targeting cancer-associated glycans as a therapeutic strategy in leukemia. <i>International Journal of Transgender Health</i> , 2022, 15, 378-433.	1.1	2
259	Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage. <i>Cancers</i> , 2022, 14, 1540.	1.7	11
260	Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 381-392.	1.3	7
261	CAR-NK cells for cancer immunotherapy: from bench to bedside. <i>Biomarker Research</i> , 2022, 10, 12.	2.8	65
262	Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 831848.	2.2	1
263	Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3207.	1.8	7
264	Efficiency of Electronic Health Record Assessment of Patient-Reported Outcomes After Cancer Immunotherapy. <i>JAMA Network Open</i> , 2022, 5, e224427.	2.8	18
265	Biomimetic Nanocarriers Guide Extracellular ATP Homeostasis to Remodel Energy Metabolism for Activating Innate and Adaptive Immunity System. <i>Advanced Science</i> , 2022, 9, e2105376.	5.6	27
266	An updated narrative review on the management of the most common oncological and hematological emergencies. <i>Disease-a-Month</i> , 2023, 69, 101355.	0.4	1
267	Targeting mitochondria for cancer photodynamic therapy. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 38, 102830.	1.3	32
268	Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse models. <i>Cancer Letters</i> , 2022, 535, 215661.	3.2	12
269	Iron (Fe)-doped mesoporous 45S5 bioactive glasses: Implications for cancer therapy. <i>Translational Oncology</i> , 2022, 20, 101397.	1.7	26
270	Can Immune-related adverse events serve as clinical biomarkers of PD-1/PD-L1 inhibitor efficacy in Pan-Cancer Patients?. <i>International Immunopharmacology</i> , 2022, 108, 108738.	1.7	1
271	Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 367.	3.5	72
272	microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1. <i>Bioengineered</i> , 2022, 13, 917-929.	1.4	15
273	PD-L1 expression and immune cells infiltration in primary tracheobronchial neoplasm. <i>Translational Lung Cancer Research</i> , 2021, 10, 4617-4630.	1.3	2
274	Results of combined nivolumab and ipilimumab therapy in patients with cancer. <i>Meditinskiy Sovet</i> , 2021, , 18-23.	0.1	0
275	Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features. <i>Frontiers in Immunology</i> , 2022, 13, 875093.	2.2	10

#	ARTICLE	IF	CITATIONS
276	Construction of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in thymic epithelial tumors. <i>Bioscience Reports</i> , 2022, 42, .	1.1	2
277	Establishment of a Prognostic Model of Lung Adenocarcinoma Based on Tumor Heterogeneity. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 807497.	1.6	6
278	Sleep During Oncological Treatment – A Systematic Review and Meta-Analysis of Associations With Treatment Response, Time to Progression and Survival. <i>Frontiers in Neuroscience</i> , 2022, 16, 817837.	1.4	9
279	Reptiles as Promising Sources of Medicinal Natural Products for Cancer Therapeutic Drugs. <i>Pharmaceutics</i> , 2022, 14, 874.	2.0	3
280	Modulating tumor physical microenvironment for fueling CAR-T cell therapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 185, 114301.	6.6	28
291	The 2021 Dr. Robert D. and Alma W. Moreton Research Award and Commemorative Lectureship: Paradoxical Role of Intestinal Stromal Cells in Healing and Disease. <i>Southern Medical Journal</i> , 2022, 115, 35-37.	0.3	0
293	Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy. <i>World Journal of Oncology</i> , 2022, 13, 49-52.	0.6	8
294	Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma via Single-Cell Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 871769.	2.2	8
295	Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors. <i>Materials and Design</i> , 2022, 219, 110738.	3.3	0
296	Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases. <i>Journal of the Neurological Sciences</i> , 2022, 438, 120275.	0.3	5
297	Neurotoxicity as a rare side effect of immune checkpoint inhibitors. A case report and review of the literature. <i>Memo - Magazine of European Medical Oncology</i> , 0, .	0.3	1
298	The oncogenic role of tubulin alpha-1c chain in human tumours. <i>BMC Cancer</i> , 2022, 22, 498.	1.1	8
299	Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature. <i>Journal of Clinical Medicine</i> , 2022, 11, 2629.	1.0	6
300	Development of Anticancer Peptides Using Artificial Intelligence and Combinational Therapy for Cancer Therapeutics. <i>Pharmaceutics</i> , 2022, 14, 997.	2.0	19
301	Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer. <i>International Immunopharmacology</i> , 2022, 108, 108803.	1.7	5
302	Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life. <i>Current Medical Research and Opinion</i> , 2022, 38, 1361-1368.	0.9	4
303	Novel Insights on Lipid Metabolism Alterations in Drug Resistance in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	35
304	An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, 8230.	1.6	9

#	ARTICLE	IF	CITATIONS
306	Construction and validation of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	2
307	Function and therapeutic development of exosomes for cancer therapy. <i>Archives of Pharmacal Research</i> , 2022, 45, 295-308.	2.7	15
308	PTBP1 as a Promising Predictor of Poor Prognosis by Regulating Cell Proliferation, Immunosuppression, and Drug Sensitivity in SARC. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-26.	1.9	9
309	Role of Licochalcone A in Potential Pharmacological Therapy: A Review. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	15
310	Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways. <i>Molecules</i> , 2022, 27, 3513.	1.7	12
311	Glioblastoma: two immune subtypes under the surface of the cold tumor. <i>Aging</i> , 2022, 14, 4357-4375.	1.4	3
312	Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 625-637.	8.2	239
313	Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	19
314	Immunotherapy toxicities: An SGO clinical practice statement. <i>Gynecologic Oncology</i> , 2022, , .	0.6	1
315	Screening of immune cell activators from Astragali Radix using a comprehensive two-dimensional NK-92MI cell membrane chromatography/C18 column/time-of-flight mass spectrometry system. <i>Journal of Pharmaceutical Analysis</i> , 2022, 12, 725-732.	2.4	6
316	Targeting primary and metastatic tumor growth in an aggressive breast cancer by engineered tryptophan auxotrophic Salmonella Typhimurium. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 350-363.	2.0	9
317	Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysis. <i>Gland Surgery</i> , 2022, 11, 1026-1036.	0.5	2
318	Magnetic hyperthermia induces effective and genuine immunogenic tumor cell death with respect to exogenous heating. <i>Journal of Materials Chemistry B</i> , 2022, 10, 5364-5374.	2.9	16
319	Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 691-702.	0.9	5
320	Mechanisms underlying immune-related adverse events during checkpoint immunotherapy. <i>Clinical Science</i> , 2022, 136, 771-785.	1.8	2
321	PET imaging of an optimized anti-PD-L1 probe 68Ga-NODAGA-BMS986192 in immunocompetent mice and non-human primates. <i>EJNMMI Research</i> , 2022, 12, .	1.1	7
322	Glucose Metabolism Intervention-Facilitated Nanomedicine Therapy. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 2707-2731.	3.3	9
323	PD-1 Inhibitor-Induced Thyrotoxicosis Associated with Coronary Artery Spasm and Ventricular Tachycardia. <i>Cardiovascular Toxicology</i> , 0, , .	1.1	3

#	ARTICLE	IF	CITATIONS
324	Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
326	Expression of ALG3 in Hepatocellular Carcinoma and Its Clinical Implication. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	2
327	Clinical evidence for synergy between immunotherapy and radiotherapy (<scp>SITAR</scp>). <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 881-895.	0.9	9
328	Cancer Immunotherapy and Cytotoxicity: Current Advances and Challenges. , 0, , .		0
329	CLEC1B is a Promising Prognostic Biomarker and Correlated with Immune Infiltration in Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 0, Volume 15, 5661-5672.	0.8	3
330	Immune Checkpoint Inhibitor Associated Autoimmune Encephalitis, Rare and Novel Topic of Neuroimmunology: A Case Report and Review of the Literature. <i>Brain Sciences</i> , 2022, 12, 773.	1.1	7
331	Spatial delivery of immune cues to lymph nodes to define therapeutic outcomes in cancer vaccination. <i>Biomaterials Science</i> , 2022, 10, 4612-4626.	2.6	2
332	Real World Study of Immune-Related Adverse Events Caused by PD-1 Inhibitors. <i>Advances in Clinical Medicine</i> , 2022, 12, 5913-5936.	0.0	0
333	Systemically targeted cancer immunotherapy and gene delivery using transmorphic particles. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	12
334	Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1757-1766.	1.8	6
335	NAV3 Is a Novel Prognostic Biomarker Affecting the Immune Status of the Tumor Microenvironment in Colorectal Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-19.	0.9	2
336	Natural products and their derivatives as immune check point inhibitors: Targeting cytokine/chemokine signalling in cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 214-232.	4.3	21
337	Nanomaterials as Novel Biomarkers for Cancer Nanotheranostics: State of the Art. , 0, , .		0
338	Assembling p53 Activating Peptide With CeO ₂ Nanoparticle to Construct a Metallo-Organic Supermolecule Toward the Synergistic Ferroptosis of Tumor. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	7
339	Mechanisms of cancer cell killing by metformin: a review on different cell death pathways. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 197-214.	1.4	15
340	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
341	Glioblastoma in Patients With Multiple Sclerosis. <i>Neurohospitalist</i> , The, 0, , 194187442211060.	0.3	0
342	Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3

#	ARTICLE	IF	CITATIONS
343	In vivo multidimensional CRISPR screens identify <i>Lgals2</i> as an immunotherapy target in triple-negative breast cancer. <i>Science Advances</i> , 2022, 8, .	4.7	26
344	Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-27.	0.6	5
345	Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
346	The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	1
347	Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance. <i>Genome Medicine</i> , 2022, 14, .	3.6	20
348	Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
349	Immune-related adverse events of cancer immunotherapies targeting kinases. , 2022, , 108250.		1
350	Generation, secretion and degradation of cancer immunotherapy target PD-L1. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	5
351	Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	58
352	Upregulation of MHC-I and downregulation of PD-L1 expression by doxorubicin and deferasirox codelivered liposomal nanoparticles for chemoimmunotherapy of melanoma. <i>International Journal of Pharmaceutics</i> , 2022, 624, 122002.	2.6	5
353	Exosomes in urological diseases - Biological functions and clinical applications. <i>Cancer Letters</i> , 2022, 544, 215809.	3.2	10
354	Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
355	Improving cancer immunotherapy via co-delivering checkpoint blockade and thrombospondin-1 downregulator. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 3503-3517.	5.7	12
356	Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, , 102591.	1.7	2
358	Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer. <i>Human Antibodies</i> , 2022, , 1-20.	0.6	0
359	<sc>Nanoalbuminâ€“prodrug</sc> conjugates prepared via a <sc>thiolationâ€“andâ€“conjugation</sc> method improve cancer chemotherapy and immune checkpoint blockade therapy by promoting <sc>CD8</sc> ⁺ Tâ€“cell infiltration. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	2
360	Radiotherapy combined with immunotherapy: the dawn of cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	142
361	When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 1589.	2.0	10

#	ARTICLE	IF	CITATIONS
362	A multi-omic approach reveals utility of CD45 expression in prognosis and novel target discovery. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	7
363	Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
364	Significance of ZEB2 in the immune microenvironment of colon cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
365	Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	33
366	Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies. <i>Pharmaceutics</i> , 2022, 14, 1762.	2.0	4
367	EMT-Related Gene Signature Predicts the Prognosis in Uveal Melanoma Patients. <i>Journal of Oncology</i> , 2022, 2022, 1-19.	0.6	5
368	Pan-Cancer Analysis of the Oncogenic and Immunological Role of Solute Carrier Family 6 Member 8 (SLC6A8). <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
369	Cancer Immunotherapy and Delivery System: An Update. <i>Pharmaceutics</i> , 2022, 14, 1630.	2.0	12
370	Application of nanotechnology in CAR-T-cell immunotherapy. <i>Chinese Chemical Letters</i> , 2023, 34, 107747.	4.8	5
371	Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
372	Association between serum baseline C1q and IgG levels and the efficacy of combined immunotherapy in patients with esophageal squamous cell carcinoma: a retrospective study. <i>Immunopharmacology and Immunotoxicology</i> , 0, , 1-24.	1.1	0
373	SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer. <i>Aging</i> , 2022, 14, 6316-6337.	1.4	6
374	Emerging advances in engineered macrophages for tumor immunotherapy. <i>Cytotherapy</i> , 2022, , .	0.3	1
375	Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer. <i>Cancer Management and Research</i> , 0, Volume 14, 2469-2483.	0.9	5
376	Engineered extracellular vesicles and their mimetics for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 349, 679-698.	4.8	74
377	Association between germ-line HLA and immune-related adverse events. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
378	Cancer therapeutics and gut microflora. , 2022, , 207-231.		0
379	Colorectal Cancer Cell Differentiation Trajectory Predicts Patient Immunotherapy Response and Prognosis. <i>Cancer Control</i> , 2022, 29, 107327482211213.	0.7	1

#	ARTICLE	IF	CITATIONS
380	Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. <i>Theranostics</i> , 2022, 12, 6273-6290.	4.6	25
381	Role of Endomyocardial Biopsy in Diagnostics of Myocarditis. <i>Diagnostics</i> , 2022, 12, 2104.	1.3	6
382	Medicinal Plants in the Regulation of PD-L1/PD-1 Immune Checkpoint of Various Human Cancer Cells: A Narrative Review. <i>Current Cancer Therapy Reviews</i> , 2023, 19, 117-131.	0.2	0
383	Exploring dendrimer-based drug delivery systems and their potential applications in cancer immunotherapy. <i>European Polymer Journal</i> , 2022, 177, 111471.	2.6	39
384	Immune Checkpoint Inhibitor-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Squamous Cell Carcinoma. <i>Journal of Hematology (Brossard, Quebec)</i> , 2022, 11, 142-147.	0.4	6
385	Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
386	Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
387	Photocontrolled Spatiotemporal Delivery of DNA Immunomodulators for Enhancing Membrane-Targeted Tumor Photodynamic Immunotherapy. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 44183-44198.	4.0	9
388	Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10617.	1.8	17
389	Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer. <i>Joint Bone Spine</i> , 2023, 90, 105457.	0.8	3
390	Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
391	Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
392	A novel LUAD prognosis prediction model based on immune checkpoint-related lncRNAs. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
393	PRR15 Is a Novel Diagnostic and Prognostic Biomarker in Papillary Thyroid Cancer and Modulates the Tumor Microenvironment. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	1
394	Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
395	Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
396	Not just a gut feeling: a deep exploration of functional bacterial metabolites that can modulate host health. <i>Gut Microbes</i> , 2022, 14, .	4.3	7
397	Implantable versatile oxidized bacterial cellulose membrane for postoperative HNSCC treatment via photothermal-boosted immunotherapy. <i>Nano Research</i> , 2023, 16, 951-963.	5.8	11

#	ARTICLE	IF	CITATIONS
398	Myocarditis Induced by Immunotherapy in Metastatic Melanoma—Review of Literature and Current Guidelines. <i>Journal of Clinical Medicine</i> , 2022, 11, 5182.	1.0	2
399	TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity. , 2022, 10, e004725.		8
400	Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e30151.	0.4	0
401	Melanoma Management: From Epidemiology to Treatment and Latest Advances. <i>Cancers</i> , 2022, 14, 4652.	1.7	32
402	Emerging Trends in Immunotherapy for Cancer. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 60.	1.0	17
403	Exploring the oncogenic roles of LINC00857 in pan-cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
405	Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data. <i>Acta Oncologica</i> , 2022, 61, 1157-1161.	0.8	4
406	Modulation of the Gut Microbiome to Enhance Immunotherapy Response in Metastatic Melanoma Patients: A Clinical Review. <i>Dermatology and Therapy</i> , 2022, 12, 2489-2497.	1.4	7
407	Bacterial outer membrane vesicle-based cancer nanovaccines. <i>Cancer Biology and Medicine</i> , 2022, 19, 1290-1300.	1.4	14
408	Anti-tumour potential of <sc>PD</sc> post-translational modifications. <i>Immunology</i> , 2022, 167, 471-481.	2.0	10
409	Comprehensive analysis of cuproptosis in immune response and prognosis of osteosarcoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
410	Role of copper ionophore-induced death in immune microenvironment and clinical prognosis of ccRCC: An integrated analysis. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
411	Application of Cytochrome C-Related Genes in Prognosis and Treatment Prediction of Lung Adenocarcinoma. <i>Disease Markers</i> , 2022, 2022, 1-19.	0.6	0
412	Distepharinamide, a novel dimeric proaporphine alkaloid from <i>Diploclisia glaucescens</i> , inhibits the differentiation and proliferative expansion of CD4 ⁺ Foxp3 ⁺ regulatory T cells. <i>Phytomedicine</i> , 2022, 107, 154482.	2.3	1
413	Upregulated YTHDF1 associates with tumor immune microenvironment in head and neck squamous cell carcinomas. <i>Translational Cancer Research</i> , 2022, 11, 3986-3999.	0.4	2
414	A Redox-responsive Prodrug Nanogel of TLR7/8 Agonist for Improved Cancer Immunotherapy. <i>Chinese Journal of Polymer Science (English Edition)</i> , 2023, 41, 32-39.	2.0	2
415	Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. <i>Biology of Sex Differences</i> , 2022, 13, .	1.8	9
416	Artificial intelligence for multimodal data integration in oncology. <i>Cancer Cell</i> , 2022, 40, 1095-1110.	7.7	115

#	ARTICLE	IF	CITATIONS
417	Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
419	High Expression of COL10A1 Is an Independent Predictive Poor Prognostic Biomarker and Associated with Immune Infiltration in Advanced Gastric Cancer Microenvironment. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	3
421	Significance of macrophage infiltration in the prognosis of lung adenocarcinoma patients evaluated by scRNA and bulkRNA analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
422	Combined Immunotherapy and Targeted Therapies for Cancer Treatment: recent advances and future perspectives. <i>Current Cancer Drug Targets</i> , 2022, 23, .	0.8	0
424	Targeting FGL2 in glioma immunosuppression and malignant progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
425	Comprehensive Analysis of NPSR1-AS1 as a Novel Diagnostic and Prognostic Biomarker Involved in Immune Infiltrates in Lung Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	4
426	Bioinformatic analysis of FOXN3 expression and prognostic value in pancreatic cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
427	Identification of TIMP2 as a Prognostic Biomarker and Its Correlation with Tumor Immune Microenvironment: A Comprehensive Pan-Cancer Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	1
428	Immunotheranostic microbubbles (iMBs) - a modular platform for dendritic cell vaccine delivery applied to breast cancer immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	6
429	Cellular immunotherapy for medulloblastoma. <i>Neuro-Oncology</i> , 2023, 25, 617-627.	0.6	7
430	Multimiomics surface receptor profiling of the NCI-60 tumor cell panel uncovers novel theranostics for cancer immunotherapy. <i>Cancer Cell International</i> , 2022, 22, .	1.8	1
431	Endogenous stimuli-responsive nanoparticles for cancer therapy: From bench to bedside. <i>Pharmacological Research</i> , 2022, 186, 106522.	3.1	13
432	Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression. , 2022, 10, e005503.		3
433	Reactivation of immune-related colitis during targeted therapy in a patient with metastatic cutaneous melanoma. <i>Siberian Journal of Oncology</i> , 2022, 21, 162-167.	0.1	1
434	Immune checkpoint inhibitor therapy and elevated levels of C-reactive protein associated with COVID-19 aggravation in patients with lung cancer. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2022, 8, .	0.4	1
435	New target DDR1: A "double-edged sword" in solid tumors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188829.	3.3	5
436	Comprehensive Analysis Reveals PTK6 as a Prognostic Biomarker Involved in the Immunosuppressive Microenvironment in Breast Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-14.	0.9	1
437	Novel T-cell signature based on cell pair algorithm predicts survival and immunotherapy response for patients with bladder urothelial carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5

#	ARTICLE	IF	CITATIONS
438	A Systematic Review of Systematic Reviews and Pooled Meta-Analysis on Psychosocial Interventions for Improving Cancer-Related Fatigue. <i>Seminars in Oncology Nursing</i> , 2022, , 151354.	0.7	4
439	Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation. <i>Chemical Society Reviews</i> , 2023, 52, 47-96.	18.7	19
440	Immunotherapy for cancer. <i>Medicine</i> , 2023, 51, 37-41.	0.2	0
441	Research progress on the antitumor effects of astragaloside IV. <i>European Journal of Pharmacology</i> , 2023, 938, 175449.	1.7	8
442	Oncologic Emergencies: Pathophysiology, Diagnosis, and Initial Management. , 2022, , .		0
443	A tumor vasculatureâ€“based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors. <i>Science Advances</i> , 2022, 8, .	4.7	6
444	Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15006.	1.8	4
445	Women at heart: Introducing gender cardio-oncology. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	4
446	Gut microbiota: a potential target for improved cancer therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 541-552.	1.2	4
447	Macrophage renewal modes affect acquired resistance to gefitinib in EGFRâ€“mutant lung cancer PCâ€“9 cells. <i>Oncology Reports</i> , 2022, 49, .	1.2	1
448	Editorial: Induced cell senescence as a therapeutic strategy for cancer treatment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
449	Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report. <i>Medicine (United States)</i> , 2022, 101, e32076.	0.4	2
450	A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
451	Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptorâ€“T-cell therapy. <i>Cytotherapy</i> , 2023, 25, 192-201.	0.3	2
452	Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
453	Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
454	ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors. <i>Cancers</i> , 2022, 14, 5951.	1.7	4
455	Immunotherapy for Esophageal Cancer. , 2023, , 1-22.		0

#	ARTICLE	IF	CITATIONS
456	Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials. <i>Medicine (United States)</i> , 2022, 101, e32333.	0.4	5
457	Safety Profiling of Tumor-targeted T Cell-Bispecific Antibodies with Alveolus Lung- and Colon-on-Chip. <i>Bio-protocol</i> , 2023, 13, .	0.2	1
458	Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1671-1688.	3.3	2
459	The Role of Mesenchymal Stem Cells in Cancer Immunotherapy. <i>Current Stem Cell Research and Therapy</i> , 2023, 18, 1056-1068.	0.6	0
460	The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
461	The lung, the niche, and the microbe: Exploring the lung microbiome in cancer and immunity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
462	Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer. <i>Genes and Diseases</i> , 2024, 11, 218-233.	1.5	6
464	Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis. <i>Immunotherapy</i> , 2023, 15, 189-207.	1.0	3
465	HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 737-747.	1.2	3
466	Epigenetic Perspective of Immunotherapy for Cancers. <i>Cells</i> , 2023, 12, 365.	1.8	4
467	Comprehensive analysis regarding the prognostic significance of downregulated ferroptosis-related gene AKR1C2 in gastric cancer and its underlying roles in immune response. <i>PLoS ONE</i> , 2023, 18, e0280989.	1.1	1
468	Metal ions and nanometallic materials in antitumor immunity: Function, application, and perspective. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	16
469	Elafin is related to immune infiltration and could predict the poor prognosis in ovarian cancer. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
470	Immune Checkpoint Inhibitor-Induced Primary Hyperparathyroidism in a Small-Cell Lung Cancer Patient: A Case Report. <i>Medicina (Lithuania)</i> , 2023, 59, 215.	0.8	2
471	Multifunctional gold nanorods in low-temperature photothermal interactions for combined tumor starvation and RNA interference therapy. <i>Acta Biomaterialia</i> , 2023, 159, 324-337.	4.1	9
472	A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy. <i>Biomedicines</i> , 2023, 11, 323.	1.4	1
473	Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1381-1394.	2.0	3
474	Advances in Natural Killer Cells and Immunotherapy for Gastric Cancer. , 0, , .		0

#	ARTICLE	IF	CITATIONS
475	Immunotherapy for Breast Cancer. , 2023, , 1-30.		0
476	Exosome-Associated Gene Signature for Predicting the Prognosis of Ovarian Cancer Patients. Journal of Immunology Research, 2023, 2023, 1-17.	0.9	3
477	Comprehensive Molecular Analyses of Notch Pathway-Related Genes to Predict Prognosis and Immunotherapy Response in Patients with Gastric Cancer. Journal of Oncology, 2023, 2023, 1-15.	0.6	1
478	The Role of Exosomes in Tumor Metastasis. , 2023, , 1-29.		0
479	Advancing CAR T cell therapy through the use of multidimensional omics data. Nature Reviews Clinical Oncology, 2023, 20, 211-228.	12.5	30
482	The application of nanoparticles in immunotherapy for hepatocellular carcinoma. Journal of Controlled Release, 2023, 355, 85-108.	4.8	3
483	The Characteristics of Tumor Microenvironment Predict Survival and Response to Immunotherapy in Adrenocortical Carcinomas. Cells, 2023, 12, 755.	1.8	5
484	Identification of the Immune Subtypes for the Prediction of Metastasis in Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2023, 113, 719-735.	1.2	0
485	A Comprehensive Review on Cannabis sativa Ethnobotany, Phytochemistry, Molecular Docking and Biological Activities. Plants, 2023, 12, 1245.	1.6	10
486	Regulating tumor cholesterol microenvironment to enhance photoimmunotherapy in oral squamous cell carcinoma. Chemical Engineering Journal, 2023, 462, 142160.	6.6	2
487	Recent advances in aptamer-based therapeutic strategies for targeting cancer stem cells. Materials Today Bio, 2023, 19, 100605.	2.6	3
489	Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives. Molecular Cancer, 2023, 22, .	7.9	3
490	Integrated multiomics analyses unveil the implication of a costimulatory molecule score on tumor aggressiveness and immune evasion in breast cancer: A large-scale study through over 8,000 patients. Computers in Biology and Medicine, 2023, 159, 106866.	3.9	0
491	Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches. Biomarker Research, 2023, 11, .	2.8	2
492	Symptoms, symptom clusters and associated factors among cancer patients receiving immune checkpoint inhibitor therapy: A cross-sectional survey. European Journal of Oncology Nursing, 2023, 63, 102288.	0.9	0
493	Immunomodulatory glycomedicine: Introducing next generation cancer glycovaccines. Biotechnology Advances, 2023, 65, 108144.	6.0	8
496	Natural peptides for immunological regulation in cancer therapy: Mechanism, facts and perspectives. Biomedicine and Pharmacotherapy, 2023, 159, 114257.	2.5	14
497	Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy. Critical Reviews in Oncology/Hematology, 2023, 182, 103923.	2.0	1

#	ARTICLE	IF	CITATIONS
498	Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. <i>Immunotherapy</i> , 2023, 15, 117-126.	1.0	2
499	Radiotherapy/Chemotherapy-Immunotherapy for Cancer Management: From Mechanisms to Clinical Implications. <i>Oxidative Medicine and Cellular Longevity</i> , 2023, 2023, 1-9.	1.9	5
500	Bioresponsive Self-Reinforcing Sericin/Silk Fibroin Hydrogel for Relieving the Immune-Related Adverse Events in Tumor Immunotherapy. <i>Advanced Functional Materials</i> , 2023, 33, .	7.8	4
501	Boosting Checkpoint Immunotherapy with Biomaterials. <i>ACS Nano</i> , 2023, 17, 3225-3258.	7.3	20
502	Nanomodified Switch Induced Precise and Moderate Activation of CAR-T Cells for Solid Tumors. <i>Advanced Science</i> , 2023, 10, .	5.6	2
503	Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1. <i>Molecular Therapy - Oncolytics</i> , 2023, 28, 334-348.	2.0	3
505	The Role of Cytoskeleton Protein 4.1 in Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3777.	1.8	1
506	How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles. <i>Cancers</i> , 2023, 15, 1324.	1.7	1
507	The role of m6A-mediated PD-1/PD-L1 in antitumor immunity. <i>Biochemical Pharmacology</i> , 2023, 210, 115460.	2.0	2
508	Case report: PD-1 inhibitor-based treatment strategies in gastric cancer complicated by bone marrow metastasis and disseminated intravascular coagulation: A report of two cases. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
509	Imaging assessment of toxicity related to immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
510	The diagnostic and therapeutic prospects of exosomes in ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2023, 130, 999-1006.	1.1	2
511	Tumor Microenvironment Regulation and Cancer Targeting Therapy Based on Nanoparticles. <i>Journal of Functional Biomaterials</i> , 2023, 14, 136.	1.8	1
512	Endocrine and Neurological Toxicities of Immunotherapies. <i>Praxis</i> , 2023, 112, 178-183.	0.2	1
513	Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta-analysis of randomized controlled trials. <i>Thoracic Cancer</i> , 2023, 14, 1029-1035.	0.8	1
514	Programmed Cell Death Protein 1 Inhibitor-Mediated Peripheral Neuropathy. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100495.	0.6	0
515	Emerging phagocytosis checkpoints in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	32
516	Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0

#	ARTICLE	IF	CITATIONS
517	Polysaccharide-Based Stimulus-Responsive Nanomedicines for Combination Cancer Immunotherapy. <i>Small</i> , 2023, 19, .	5.2	13
518	Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
519	Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	2
520	Recombinant cell-penetrating trichosanthin synergizes anti-PD-1 therapy in colorectal tumor. <i>International Journal of Biological Sciences</i> , 2023, 19, 1698-1712.	2.6	3
521	Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer. <i>Journal of Personalized Medicine</i> , 2023, 13, 526.	1.1	5
522	Nanobiotechnology-mediated radioimmunotherapy treatment for triple-negative breast cancer. , 2023, 2, .		0
523	Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
524	Safety analysis of antineoplastic drugs for lung cancer: a retrospective analysis based on Shaanxi Province in Western China. <i>Expert Opinion on Drug Safety</i> , 2024, 23, 99-105.	1.0	1
526	Oral Toxicities in Cancer Patients, Who Receive Immunotherapy: A Case Series of 24 Patients. <i>Oral</i> , 2023, 3, 123-133.	0.6	1
527	A novel 7-chemokine-genes predictive signature for prognosis and therapeutic response in renal clear cell carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
528	Integrating single-cell analysis and machine learning to create glycosylation-based gene signature for prognostic prediction of uveal melanoma. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	21
529	Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis. <i>Drug Development Research</i> , 2023, 84, 654-670.	1.4	4
530	COX7B Is a New Prognostic Biomarker and Correlates with Tumor Immunity in Esophageal Carcinoma. <i>Mediators of Inflammation</i> , 2023, 2023, 1-11.	1.4	0
531	Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	14
532	Exosome-based nanoimmunotherapy targeting TAMs, a promising strategy for glioma. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	12
533	Toxicokinetics and organ-specific toxicity. , 2023, , 267-288.		0
534	Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy. <i>Nature Communications</i> , 2023, 14, .	5.8	6
536	Exploration of NPC2 as a Potential Biomarker for Immunotherapy Using RNA-seq and Protein Data - A New Hypothesis. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2023, 23, .	0.6	0

#	ARTICLE	IF	CITATIONS
537	Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: A case report. <i>Medicine (United States)</i> , 2023, 102, e33550.	0.4	1
538	NKT cells contribute to alleviating lung metastasis in adenoid cystic carcinoma. , 2023, 2, .		0
539	Tumor-associated fibrosis impairs the response to immunotherapy. <i>Matrix Biology</i> , 2023, 119, 125-140.	1.5	4
540	PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS). <i>Expert Opinion on Drug Safety</i> , 2024, 23, 257-267.	1.0	0
541	UXT at the crossroads of cell death, immunity and neurodegenerative diseases. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
542	Activatable Sonoafterglow Nanoprobes for Tâ€Cell Imaging. <i>Advanced Materials</i> , 2023, 35, .	11.1	13
543	Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. <i>EClinicalMedicine</i> , 2023, 59, 101967.	3.2	11
544	Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 495-519.	0.8	12
545	Cardiotoxicities of Novel Therapies in Hematological Malignancies: Monoclonal Antibodies and Enzyme Inhibitors. <i>Current Problems in Cardiology</i> , 2023, 48, 101757.	1.1	1
610	Design, strategies, and therapeutics in nanoparticle-based siRNA delivery systems for breast cancer. <i>Journal of Materials Chemistry B</i> , 2023, 11, 8096-8116.	2.9	3
611	Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 13477-13494.	1.2	2
612	Combinational Gene Therapy toward Cancer with Nanoplatform: Strategies and Principles. <i>ACS Materials Au</i> , 2023, 3, 584-599.	2.6	5
613	The Promise of Immunotherapeutics and Vaccines in the Treatment of Cancer. , 2023, , 1-43.		1
620	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	5
622	Phytochemical-Based Nanomedicine for Targeting Tumor Microenvironment and Inhibiting Cancer Chemoresistance: Recent Advances and Pharmacological Insights. <i>Molecular Pharmaceutics</i> , 2023, 20, 5254-5277.	2.3	2
632	Breast cancer immunotherapy: a comprehensive review. <i>Clinical and Experimental Medicine</i> , 2023, 23, 4431-4447.	1.9	1
633	Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	4
642	Natural Killer Cells in Atopic Dermatitis Opening Doors to New Treatments. , 0, , .		0

#	ARTICLE	IF	CITATIONS
665	Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma. Cell Death and Disease, 2023, 14, .	2.7	0
700	Responsive biomaterials: optimizing control of cancer immunotherapy. Nature Reviews Materials, 2024, 9, 100-118.	23.3	1
714	Cancer immunotherapy-associated endocrine complications and treatment strategies. , 2024, , 199-221.		0
726	Dendrimer-based nanomedicines for cancer immunotherapy. , 2024, , 317-347.		0